Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

Table 1 Demographic and disease characteristics

	(n= 599)
Age^a (years)	56.81 (10.84)
Disease duration^b (years)	12 (20-6)
Sex,^a F (%)	457 (76.29)
CRP at baseline, median (IQR) mg/L^b	34 (17-63)
ESR at baseline, median (IQR) mg/L^b	43 (27-68)
DAS28 at baseline^a	6.36 (0.90)
Change in DAS28^a	-2.01 (1.23)
Concurrent DMARD n (%)	449 (74.96)
Infliximab	272 (45.41)
Etanercept	220 (36.73)
Adalimumab	107 (17.86)

CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; F, female; IQR, interquartile range; SD, standard deviation. ^aValues are expressed as mean (SD). ^bValues are expressed as median (IQR). All other values are n (%). Disease duration was measured in 598 patients; erythrocyte sedimentation rate (ESR) levels were measured in 578 patients; and change in DAS28 was measured in 442 patients.

ISSN: 1478-6362